After a flurry of deals over the past week from Eli Lilly, Merck and Biogen, analysts predict more M&A action from other big names, including Novartis, Amgen and AbbVie.
Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts Read More »
Clinicians’ use of an AI scribe was associated with 13 fewer minutes each day inside electronic health records and 16 fewer minutes on documenting patient care, according to the research published in JAMA.
AI scribe adoption linked to modest reductions in EHR, documentation time: study Read More »
Community Health Systems completed the divestiture of Crestwood Medical Center this week as the for-profit operator continues paying down its debt.
View Point sells tumor tissue localization devices that could complement Merit’s existing presence in the sector.
After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to defend oral Wegovy, which has been enjoying a record-breaking launch since January.
With CBER director Vinay Prasad set to depart the agency at the end of the month, a coalition of patient groups and biotech executives penned a letter imploring the Trump administration to “restore regulatory clarity” for rare disease therapies. Experts on a BioSpace panel last week also acknowledged the challenges faced by a more stringent
Rare Disease Leaders Call for Regulatory Clarity as FDA Balances Urgency With Rigor Read More »
COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment challenges.
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment Read More »
As Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S. in alignment with Trump’s Most Favored Nation policy, patients will suffer.
Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling Read More »
In this episode of Denatured, you’ll listen to Dr. Marc Hedrick, President and CEO of Plus Therapeutics and Dr. Phil Kantoff, CEO & Co-founder of Convergent Therapeutics. They discuss breakthroughs like alpha-emitting isotopes, supply chain solutions and why radiotherapeutics is biotech’s next big frontier.
The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment Read More »
Drug discovery can be an uphill battle, especially lately given recent upheaval at the FDA and muted investment activity. BioSpace spoke to four industry executives about key issues facing those working in this space, starting with planning around uncertainty.
Innovation Pressure Cooker: Tackling Drug Discovery’s Biggest Challenges Read More »
